X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pfizer India: First quarter of Wyeth consolidation - Views on News from Equitymaster
StockSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jul 16, 2015 - Pfizer India: First quarter of Wyeth consolidation

Pfizer India: First quarter of Wyeth consolidation
Jul 16, 2015

Pfizer India has announced its 4QFY15 results. The company has reported an 81.3% YoY growth in net sales and a decline of 23.8% YoY in net profits. Here is our analysis of the results.

Performance summary
  • Net sales were up by 81.3% YoY. The operating margins stood at 26.9% for the quarter. The net profits were down by 23.8% YoY.
  • Please note, this is the first quarter post amalgamation with Wyeth, hence the financials are not comparable. In the subsequent paragraphs, we will discuss the adjusted growth and key highlights in this consolidation.

Financial performance: A snapshot
(Rs m) 4QFY14 4QFY15 Change FY14 FY15 Change
Net sales 2,517 4,563 81.3% 10,043 18,277 82.0%
Other operating income 228 68 -70.2% 1,075 256 -76.2%
Expenditure 2,016 3,383 67.8% 8,733 14,703 68.4%
Operating profit (EBDITA) 729 1,248 71.1% 2,385 3,830 60.6%
EBDITA margin (%) 26.6% 26.9%   21.5% 20.7%  
Other income 163 188 15.1% 1,094 674 -38.4%
Interest (net) 1.9 1.7 -10.5% 4 8 113.9%
Depreciation 20 336 1557.1% 80 1,311  
Profit before tax 870 1,097 26.1% 3,396 3,185 -6.2%
Exceptional Item - -   - (804)  
Tax 310 671 116.5% 1,188 1,377 15.9%
Profit after tax/(loss) 560 427 -23.8% 2,208 1,004 -54.5%
Net profit margin (%) 20.4% 9.2%   22.0% 5.5%  
No. of shares (m)       29.8 29.8  
Diluted earnings per share (Rs)         34.8  
Price to earnings ratio (x)*         60.8  
* On a trailing 12 months basis

What has driven performance in 4QFY15 and FY15?
  • On like to like basis, Pfizer’s sales including Wyeth for the full year grew by 12% YoY. One of Pfizer’s key products Corex (Codeine) has been facing regulatory challenges in some geographies in India. This had impacted the sales for the quarter. Excluding Corex, the growth is 14% YoY. For the quarter, the growth was 6% YoY for Pfizer. This was largely driven by Gelusil, which was promoted through credit schemes.

  • The EBITDA margins for the year stood at 21% on a like to like basis.

  • Further, excluding the incremental impact of depreciation of approx Rs 1,180 m for the year and VRS related costs of Rs 800 m, the bottom line has grown by 17% YoY.

  • Post amalgamation, the equity share capital for Pfizer has increased to 45.7 m shares from 29.8 m shares. This is post Pfizer allotted 15.9 m shares to Wyeth shareholders.
What to expect?

At the current price of Rs 2,116 the stock is trading at a multiple of 24 times our estimated FY17 earnings.

Since some time, the growth of MNC pharma companies has remained under pressure. However, the performance improved during the quarter. As per IMS data, the MNC pharma pack grew by 7.8% in March 2015.

Post consolidation with Wyeth, Pfizer will be able to benefit from a better portfolio.

However, since the Indian government is aggressively taking steps to bring drugs under pricing regulations, this can have negative impact. We shall soon update our FY18 estimates and target price for the company. Till then, investors can continue to Hold on to the stock of Pfizer.

We would like to gently remind you that your allocation to equities should be decided upon after keeping aside some safe cash. Also within your overall exposure to equities please ensure that you broadly follow suggested asset allocation and that no single stock comprises 5% of your portfolio.

To Read the Full Story, Subscribe or Sign In



DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
INTRODUCTION:
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.

BUSINESS ACTIVITY:
An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.

DISCIPLINARY HISTORY:
There are no outstanding litigations against the Company, it subsidiaries and its Directors.

GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT:
For the terms and conditions for research reports click here.

DETAILS OF ASSOCIATES:
Details of Associates are available here.

DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
  1. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any financial interest in the subject company.
  2. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have actual/beneficial ownership of one percent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.
  3. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any other material conflict of interest at the time of publication of the research report.
DISCLOSURE WITH REGARDS TO RECEIPT OF COMPENSATION:
  1. Neither Equitymaster nor it's Associates have received any compensation from the subject company in the past twelve months.
  2. Neither Equitymaster nor it's Associates have managed or co-managed public offering of securities for the subject company in the past twelve months.
  3. Neither Equitymaster nor it's Associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  4. Neither Equitymaster nor it's Associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  5. Neither Equitymaster nor it's Associates have received any compensation or other benefits from the subject company or third party in connection with the research report.
GENERAL DISCLOSURES:
  1. The Research Analyst has not served as an officer, director or employee of the subject company.
  2. Equitymaster or the Research Analyst has not been engaged in market making activity for the subject company.
Definitions of Terms Used:
  1. Buy recommendation: This means that the investor could consider buying the concerned stock at current market price keeping in mind the tenure and objective of the recommendation service.
  2. Hold recommendation: This means that the investor could consider holding on to the shares of the company until further update and not buy more of the stock at current market price.
  3. Buy at lower price: This means that the investor should wait for some correction in the market price so that the stock can be bought at more attractive valuations keeping in mind the tenure and the objective of the service.
  4. Sell recommendation: This means that the investor could consider selling the stock at current market price keeping in mind the objective of the recommendation service.
Feedback:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Dec 12, 2017 03:33 PM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS